Causality Between Sarcopenia and Diabetic Neuropathy

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Sep 30

PMID 39345878

Authors

Yi Fang

Xiaoqing Yuan

Qing Zhang

Juan Liu

Qing Yao

Xinhua Ye

Affiliations

Soon will be listed here.

Abstract

Background: Past studies have demonstrated that diabetic neuropathy is related to sarcopenia, but the further causal relation is still unclear. We sought to investigate the causal relationship by combining data from cross-sectional and Mendelian randomization (MR) studies.

Methods: The genome-wide association studies data were collected from the UK Biobank and the European Working Group on Sarcopenia to conduct a bi-directional two-sample MR study to explore the causality between diabetic neuropathy and relevant clinical traits of sarcopenia, including appendicular lean mass (ALM), walking speed and low hand grip strength. The inverse-variance weighted and various sensitivity analyses were used to obtain MR estimates. We also enrolled a total of 196 Type 2 diabetes patients from April 2021 to April 2024 and divided them into the Distal peripheral neuropathy (DPN) group (n=51) and non-DPN group (n=145) via vibration perception threshold (VPT) and neuropathy deficit score. Logistic regression and ROC curve analysis were used to investigate the relationship between DPN and relevant sarcopenia clinical features.

Results: According to a forward MR analysis, decreased walking speed (OR: 0.04, 95% confidence interval (CI): 0.01-0.16; P<0.001) and increased ALM (1.25 [1.05-1.50], P=0.012) had a causal effect on developing diabetic neuropathy. According to reverse MR results, developing diabetic neuropathy had a causal effect on decreased walking speed (0.99 [0.99-1.00], P=0.007) and low grip strength (1.05 [1.02-1.08], P<0.001). The cross-sectional study showed that 5-time stand time (P=0.002) and 6-meter walking speed (P=0.009) had an inverse association with DPN. Additionally, we discovered that ASMI (P=0.030) and 5-time stand time (P=0.013) were separate risk factors for DPN.ConclusionThe MR study suggested that diabetic neuropathy may have a causality with relevant clinical traits of sarcopenia, and our cross-sectional study further proved that sarcopenia indexes are predictors of diabetic neuropathy.

Citing Articles

Causal relationships between plasma lipidome and diabetic neuropathy: a Mendelian randomization study.

Wang Z, Liu Z, Yang Q, Qiao H, Yin Y, Zhao Z Front Endocrinol (Lausanne). 2025; 15:1398691.

PMID: 39882262 PMC: 11774734. DOI: 10.3389/fendo.2024.1398691.

Development and Validation of a Risk Prediction Model for Sarcopenia in Chinese Older Patients with Type 2 Diabetes Mellitus.

Wang X, Gao S Diabetes Metab Syndr Obes. 2024; 17:4611-4626.

PMID: 39635500 PMC: 11616483. DOI: 10.2147/DMSO.S493903.

References

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

. Diabetic neuropathy. Nat Rev Dis Primers. 2019; 5(1):42. PMC: 7096070. DOI: 10.1038/s41572-019-0097-9. View

Yang Q, Zhang Y, Zeng Q, Yang C, Shi J, Zhang C . Correlation Between Diabetic Peripheral Neuropathy and Sarcopenia in Patients with Type 2 Diabetes Mellitus and Diabetic Foot Disease: A Cross-Sectional Study. Diabetes Metab Syndr Obes. 2020; 13:377-386. PMC: 7025667. DOI: 10.2147/DMSO.S237362. View

Skrivankova V, Richmond R, Woolf B, Yarmolinsky J, Davies N, Swanson S . Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021; 326(16):1614-1621. DOI: 10.1001/jama.2021.18236. View

Burgess S, Thompson S . Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011; 40(3):755-64. DOI: 10.1093/ije/dyr036. View

Zaino B, Goel R, Devaragudi S, Prakash A, Vaghamashi Y, Sethi Y . Diabetic neuropathy: Pathogenesis and evolving principles of management. Dis Mon. 2023; 69(9):101582. DOI: 10.1016/j.disamonth.2023.101582. View

Boulton A, Vinik A, Arezzo J, Bril V, Feldman E, Freeman R . Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005; 28(4):956-62. DOI: 10.2337/diacare.28.4.956. View

Andersen H, Gjerstad M, Jakobsen J . Atrophy of foot muscles: a measure of diabetic neuropathy. Diabetes Care. 2004; 27(10):2382-5. DOI: 10.2337/diacare.27.10.2382. View

Burgess S, Butterworth A, Thompson S . Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013; 37(7):658-65. PMC: 4377079. DOI: 10.1002/gepi.21758. View

10.

Roberts H, Denison H, Martin H, Patel H, Syddall H, Cooper C . A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011; 40(4):423-9. DOI: 10.1093/ageing/afr051. View

11.

Pei Y, Liu Y, Yang X, Zhang H, Feng G, Wei X . The genetic architecture of appendicular lean mass characterized by association analysis in the UK Biobank study. Commun Biol. 2020; 3(1):608. PMC: 7585446. DOI: 10.1038/s42003-020-01334-0. View

12.

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

13.

Selvarajah D, Kar D, Khunti K, Davies M, Scott A, Walker J . Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019; 7(12):938-948. DOI: 10.1016/S2213-8587(19)30081-6. View

14.

Garrow A, Boulton A . Vibration perception threshold--a valuable assessment of neural dysfunction in people with diabetes. Diabetes Metab Res Rev. 2006; 22(5):411-9. DOI: 10.1002/dmrr.657. View

15.

Chen S, Yan S, Aiheti N, Kuribanjiang K, Yao X, Wang Q . A bi-directional Mendelian randomization study of sarcopenia-related traits and type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14:1109800. PMC: 10031051. DOI: 10.3389/fendo.2023.1109800. View

16.

Zhang Y, Shen X, He L, Zhao F, Yan S . Association of sarcopenia and muscle mass with both peripheral neuropathy and nerve function in patients with type 2 diabetes. Diabetes Res Clin Pract. 2020; 162:108096. DOI: 10.1016/j.diabres.2020.108096. View

17.

Liu S, Zheng H, Zhu X, Mao F, Zhang S, Shi H . Neutrophil-to-lymphocyte ratio is associated with diabetic peripheral neuropathy in type 2 diabetes patients. Diabetes Res Clin Pract. 2017; 130:90-97. DOI: 10.1016/j.diabres.2017.05.008. View

18.

Andreassen C, Jakobsen J, Andersen H . Muscle weakness: a progressive late complication in diabetic distal symmetric polyneuropathy. Diabetes. 2006; 55(3):806-12. DOI: 10.2337/diabetes.55.03.06.db05-1237. View

19.

Hartwig F, Davey Smith G, Bowden J . Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017; 46(6):1985-1998. PMC: 5837715. DOI: 10.1093/ije/dyx102. View

20.

Lawlor D, Tilling K, Davey Smith G . Triangulation in aetiological epidemiology. Int J Epidemiol. 2017; 45(6):1866-1886. PMC: 5841843. DOI: 10.1093/ije/dyw314. View